Caricamento...
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia
BACKGROUND: Benign prostatic hyperplasia (BPH) refers to non‐malignant enlargement of the prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha‐blockers (ABs) and 5‐alpha reductase inhibitors (5‐ARIs) are the mainstay of medical treatment. Recently, phosphodiesterase in...
Salvato in:
| Pubblicato in: | Cochrane Database Syst Rev |
|---|---|
| Autori principali: | , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley & Sons, Ltd
2018
|
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6517182/ https://ncbi.nlm.nih.gov/pubmed/30480763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010060.pub2 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|